Which has higher valuation & earnings, ACOG or GLAS?

Glass House Brands has lower revenue, but higher earnings than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.22M 18.97 -$20.67M -$1.10 N/A Glass House Brands N/A N/A N/A N/A N/A

Does the media favor ACOG or GLAS?

In the previous week, Alpha Cognition had 2 more articles in the media than Glass House Brands. MarketBeat recorded 5 mentions for Alpha Cognition and 3 mentions for Glass House Brands. Alpha Cognition's average media sentiment score of 1.25 beat Glass House Brands' score of 0.63 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACOG or COLL?

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Alpha Cognition. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Collegium Pharmaceutical's score of 0.09 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PHAT or ACOG?

In the previous week, Phathom Pharmaceuticals had 9 more articles in the media than Alpha Cognition. MarketBeat recorded 14 mentions for Phathom Pharmaceuticals and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Phathom Pharmaceuticals' score of 0.68 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alpha Cognition 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACOG or ASMB?

In the previous week, Assembly Biosciences had 15 more articles in the media than Alpha Cognition. MarketBeat recorded 20 mentions for Assembly Biosciences and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Assembly Biosciences' score of 0.86 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACOG or ZVRA?

In the previous week, Alpha Cognition and Alpha Cognition both had 5 articles in the media. Zevra Therapeutics' average media sentiment score of 1.77 beat Alpha Cognition's score of 1.25 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alpha Cognition (ACOG) Competitors

$8.90 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$9.07 +0.17 (+1.91%)

As of 09/11/2026 07:30 PM Eastern

Compare

ACOG vs. GLAS, COLL, PHAT, ASMB, and ZVRA

Should you buy Alpha Cognition stock or one of its competitors? Alpha Cognition's main competitors and comparable companies include Glass House Brands (GLAS), Collegium Pharmaceutical (COLL), Phathom Pharmaceuticals (PHAT), Assembly Biosciences (ASMB), and Zevra Therapeutics (ZVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alpha Cognition compare to Glass House Brands?

Alpha Cognition (NASDAQ:ACOG) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Glass House Brands has lower revenue, but higher earnings than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.97	-$20.67M	-$1.10	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

Glass House Brands has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Glass House Brands' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Glass House Brands	N/A	N/A	N/A

Alpha Cognition currently has a consensus price target of $18.00, indicating a potential upside of 102.25%. Glass House Brands has a consensus price target of $16.00, indicating a potential upside of 102.76%. Given Glass House Brands' higher possible upside, analysts clearly believe Glass House Brands is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alpha Cognition had 2 more articles in the media than Glass House Brands. MarketBeat recorded 5 mentions for Alpha Cognition and 3 mentions for Glass House Brands. Alpha Cognition's average media sentiment score of 1.25 beat Glass House Brands' score of 0.63 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alpha Cognition beats Glass House Brands on 5 of the 9 factors compared between the two stocks.

How does Alpha Cognition compare to Collegium Pharmaceutical?

Alpha Cognition (NASDAQ:ACOG) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Collegium Pharmaceutical has a net margin of 5.93% compared to Alpha Cognition's net margin of -153.61%. Collegium Pharmaceutical's return on equity of 91.43% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Alpha Cognition currently has a consensus target price of $18.00, indicating a potential upside of 102.25%. Collegium Pharmaceutical has a consensus target price of $48.50, indicating a potential upside of 113.19%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Collegium Pharmaceutical has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.97	-$20.67M	-$1.10	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.35

Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Alpha Cognition. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Collegium Pharmaceutical's score of 0.09 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Collegium Pharmaceutical beats Alpha Cognition on 9 of the 13 factors compared between the two stocks.

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 9 more articles in the media than Alpha Cognition. MarketBeat recorded 14 mentions for Phathom Pharmaceuticals and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Phathom Pharmaceuticals' score of 0.68 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alpha Cognition	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals presently has a consensus price target of $21.25, suggesting a potential upside of 154.19%. Alpha Cognition has a consensus price target of $18.00, suggesting a potential upside of 102.25%. Given Phathom Pharmaceuticals' higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has lower revenue, but higher earnings than Phathom Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.86	-$221.25M	-$1.28	N/A
Alpha Cognition	$10.22M	18.97	-$20.67M	-$1.10	N/A

Phathom Pharmaceuticals has a net margin of -41.34% compared to Alpha Cognition's net margin of -153.61%. Phathom Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Alpha Cognition	-153.61%	-54.60%	-43.47%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Alpha Cognition on 11 of the 17 factors compared between the two stocks.

How does Alpha Cognition compare to Assembly Biosciences?

Alpha Cognition (NASDAQ:ACOG) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Alpha Cognition presently has a consensus target price of $18.00, indicating a potential upside of 102.25%. Assembly Biosciences has a consensus target price of $45.60, indicating a potential upside of 53.02%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Cognition is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Assembly Biosciences had 15 more articles in the media than Alpha Cognition. MarketBeat recorded 20 mentions for Assembly Biosciences and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.25 beat Assembly Biosciences' score of 0.86 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.9% of Assembly Biosciences shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alpha Cognition has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Assembly Biosciences has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.97	-$20.67M	-$1.10	N/A
Assembly Biosciences	$72.30M	8.39	-$6.12M	$1.02	29.22

Assembly Biosciences has a net margin of -0.06% compared to Alpha Cognition's net margin of -153.61%. Assembly Biosciences' return on equity of -0.02% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

Summary

Assembly Biosciences beats Alpha Cognition on 11 of the 17 factors compared between the two stocks.

How does Alpha Cognition compare to Zevra Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Zevra Therapeutics has a net margin of 42.82% compared to Alpha Cognition's net margin of -153.61%. Zevra Therapeutics' return on equity of 54.54% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Zevra Therapeutics	42.82%	54.54%	34.15%

Alpha Cognition presently has a consensus target price of $18.00, suggesting a potential upside of 102.25%. Zevra Therapeutics has a consensus target price of $27.14, suggesting a potential upside of 126.00%. Given Zevra Therapeutics' higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Zevra Therapeutics has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.97	-$20.67M	-$1.10	N/A
Zevra Therapeutics	$106.47M	6.70	$83.23M	$0.92	13.05

35.0% of Zevra Therapeutics shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

In the previous week, Alpha Cognition and Alpha Cognition both had 5 articles in the media. Zevra Therapeutics' average media sentiment score of 1.77 beat Alpha Cognition's score of 1.25 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Zevra Therapeutics beats Alpha Cognition on 11 of the 15 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACOG vs. The Competition

Export

Metric	Alpha Cognition	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$193.82M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.72%
P/E Ratio	-8.09	799.75	274.94	25.36
Price / Sales	18.97	960.74	685.43	116.41
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	3.09	10.39	10.33	6.20
Net Income	-$20.67M	$2.85B	$3.50B	$358.50M
7 Day Performance	-6.51%	-3.61%	-3.32%	-2.35%
1 Month Performance	3.13%	0.72%	-0.53%	-3.23%
1 Year Performance	-9.18%	3.61%	23.51%	8.79%

Alpha Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACOG Alpha Cognition	4.2451 of 5 stars	$8.90 flat	$18.00 +102.2%	-9.2%	$193.82M	$10.22M	N/A	N/A	Positive News
GLAS Glass House Brands	3.3272 of 5 stars	$8.52 +0.3%	$16.00 +87.9%	N/A	$798.90M	$176.98M	N/A	N/A	Analyst Downgrade Short Interest Decrease High Trading Volume
COLL Collegium Pharmaceutical	3.212 of 5 stars	$24.30 +1.3%	$51.00 +109.9%	-39.0%	$791.11M	$808.21M	19.60	210	News Coverage Analyst Forecast
PHAT Phathom Pharmaceuticals	3.2569 of 5 stars	$9.26 -1.4%	$22.86 +146.8%	-29.4%	$749.14M	$239.66M	N/A	110	News Coverage Analyst Forecast
ASMB Assembly Biosciences	4.098 of 5 stars	$36.72 +4.4%	$45.60 +24.2%	+36.4%	$747.62M	$72.30M	36.00	100	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACOG) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Cognition (ACOG) Competitors

ACOG vs. GLAS, COLL, PHAT, ASMB, and ZVRA

How does Alpha Cognition compare to Glass House Brands?

Summary

How does Alpha Cognition compare to Collegium Pharmaceutical?

Summary

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Summary

How does Alpha Cognition compare to Assembly Biosciences?

Summary

How does Alpha Cognition compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Cognition (ACOG) Competitors

ACOG vs. GLAS, COLL, PHAT, ASMB, and ZVRA

How does Alpha Cognition compare to Glass House Brands?

Which has higher valuation & earnings, ACOG or GLAS?

Is ACOG or GLAS more profitable?

Do analysts recommend ACOG or GLAS?

Does the media favor ACOG or GLAS?

Summary

How does Alpha Cognition compare to Collegium Pharmaceutical?

Is ACOG or COLL more profitable?

Do analysts prefer ACOG or COLL?

Which has stronger earnings & valuation, ACOG or COLL?

Which has more risk and volatility, ACOG or COLL?

Does the media refer more to ACOG or COLL?

Summary

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Which has more risk and volatility, PHAT or ACOG?

Does the media prefer PHAT or ACOG?

Do analysts recommend PHAT or ACOG?

Which has preferable earnings and valuation, PHAT or ACOG?

Is PHAT or ACOG more profitable?

Do insiders & institutionals hold more shares of PHAT or ACOG?

Summary

How does Alpha Cognition compare to Assembly Biosciences?

Do analysts rate ACOG or ASMB?

Does the media favor ACOG or ASMB?

Do institutionals and insiders believe in ACOG or ASMB?

Which has more volatility & risk, ACOG or ASMB?

Which has better earnings and valuation, ACOG or ASMB?

Is ACOG or ASMB more profitable?

Summary

How does Alpha Cognition compare to Zevra Therapeutics?

Is ACOG or ZVRA more profitable?

Do analysts rate ACOG or ZVRA?

Which has preferable earnings and valuation, ACOG or ZVRA?

Do insiders & institutionals have more ownership in ACOG or ZVRA?

Which has more volatility and risk, ACOG or ZVRA?

Does the media favor ACOG or ZVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools